Australia Markets close in 3 hrs 19 mins

Immutep Limited (IMM.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.4750+0.0100 (+2.15%)
As of 12:30PM AEDT. Market open.
Full screen
Previous close0.4650
Open0.4700
Bid0.4750 x 0
Ask0.4800 x 0
Day's range0.4650 - 0.4800
52-week range0.2800 - 0.7250
Volume1,116,060
Avg. volume2,692,783
Market cap308.144M
Beta (5Y monthly)1.45
PE ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings date23 Aug 2021 - 27 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003

    SYDNEY, AUSTRALIA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the first five patients have been treated in the INSIGHT-003 study. No additional safety signals have been observed in the study which is the first time a triple combination therapy consisting of eftilagimod alpha (“efti”) and an existing approved sta

  • GlobeNewswire

    Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

    Enrolled and dosed last patient in the expansion stage of Part A (1st line non-small cell lung cancer (NSCLC)) needed to complete recruitment into all cohorts of the TACTI-002 studyInterim data from Part C (2nd line head & neck squamous cell carcinoma (HNSCC) patients) presented at SITC 2021Additional data from TACTI-002 expected to be reported in H1 calendar year 2022 SYDNEY, AUSTRALIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a bi

  • GlobeNewswire

    Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

    SYDNEY, AUSTRALIA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL 201680005401.3) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the Chinese Patent Office. This new Chinese patent follows the grant of the corresponding European and Unite